RNA
Atrium TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
RNA vs peer average
39/100
RNA vs. peer average (D vs. C)
Grade spread
A 1 · B 1 · C 3 · D 2 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
NKTX is the first available peer comparator.
Nkarta is another loose preclinical/clinical biotech comp by market cap rather than mechanism or indication; sentiment can move with biotech risk appetite more than company specifics.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
RNA
Atrium Therapeutics
NKTX
Nkarta
Grade
D
A
Momentum
28
88
Value
57
58
Sentiment
51
43
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Defensive
Constructive
Grade position vs NKTX
RNA / NKTX
Grade Position
Below peers
RNA vs. peer average (D vs. C)
39/100
Momentum
28
NKTXValue
57
NKTXSentiment
51
RNARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs RNA
NKTX is the first peer returned for this comparison set.